Review on Formulation Development of Buccal Tablet

By ensuring quality, safety, and effectiveness, formulation development is a crucial component of pharmaceutical development and is necessary for the product's therapeutic and commercial success. By bypassing the GIT and hepatic first pass impact, the buccal mode of administration offers numerous benefits, including increased patient compliance. Hardness, weight uniformity, thickness, friability, swelling index, mucoadhesive strength, surface pH, drug-excipient interaction studies, and drug content uniformity were among the metrics used to describe buccal tablets. For both systemic absorption and local administration in the oral cavity, the constant production of saliva and its subsequent swallowing might result in significant drug depletion from the dosage form and, consequently, limited bioavailability. In order to avoid the mentioned drawbacks of traditional oral dosage forms (i.e., tablets, capsules, syrups, etc.), new transmucosal routes such as nasal, rectal, vaginal, ocular, and oral mucosae are being explored as potential substitutes for current oral drug delivery methods. One of the target areas for administering medications in a wide range of dose forms is the buccal oral mucosa, especially for medications intended for systemic absorption and local distribution in the oral cavity.